Name: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway (en Inglés)
Price: 49.09 USD
Availability: InStock
Author: Kollur, Shiva Prasad
ISBN: 9781636484167

portada Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway (en Inglés)

Formato

Libro Físico

Autor

Shiva Prasad Kollur

Editorial

Eliva Press

Idioma

Inglés

N° páginas

Encuadernación

Tapa Blanda

Dimensiones

22.9 x 15.2 x 0.3 cm

Peso

0.10 kg.

ISBN13

9781636484167

Categorías

Cuestiones generales de la medicina

Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway (en Inglés)

Shiva Prasad Kollur (Autor) · Eliva Press · Tapa Blanda

Libro Nuevo

$ 49.09

$ 98.18

Ahorras: $ 49.09

50% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Miércoles 17 de Julio y el Viernes 26 de Julio.

Lo recibirás en cualquier lugar de Ecuador entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway (en Inglés)"

Non-small cell lung cancer (NSCLC) is a prominent subtype of lung carcinoma that accounts for the majority of cancer-related deaths globally, and it is responsible for about 80% to 85% of lung cancers. Mitogen-Activated Protein Kinase (MAPK) signaling pathways are a vital aspect of NSCLC, and have aided in the advancement of therapies for this carcinoma. Targeting the Ras/Raf/MEK/ERK pathway is a promising and alternative method in NSCLC treatment, which is highlighted in this book. The introduction of targeted medicines has revolutionized the treatment of patients with this carcinoma. When combined with current systems biology-driven stratagems, repurposing non-cancer drugs into new therapeutic niches presents a cost-effective and efficient technique with enhancing outcomes for discovering novel pharmacological activity. This book also highlights the successful cutting-edge techniques while focusing on NSCLC targeted therapies. The ultimate challenge will be integrating these repurposed drugs into the therapeutic regimen of patients affected with NSCLC to potentially increase lung cancer cure rates. Authors: Shiva Prasad Kollur, Anisha S Jain, Gayatri Vaidya, Poojitha B. Sridara Setty, Shivalingaiah, Ashwini Prasad, Ravindra Veerapur, Veena Malligere Ankegowda, Asad Syed, Ali. H Bhakali, Chandrashekar Srinivasa, Sharanagouda Patil, Chandan Shivamallu